NYSE: $JNJ A New Frontier in Targeted Therapy In a significant development for oncology, Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with lazertinib. This treatment is specifically indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung…